Last edition
News about "Ivonescimab "
Akeso Secures Fifth NMPA Breakthrough Designation for Ivonescimab
The breakthrough designation supports ivonescimab combined with chemotherapy for first-line treatment of advanced Biliary Tract Cancer (BTC), based on an ongoing phase-III study comparing it with durvalumab-based chemotherapy.
Ivonescimab | 07/02/2026 | By News Bureau
China Updates Ivonescimab Label After NSCLC Survival Gains
China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />
Ivonescimab | 07/01/2026 | By News Bureau | 244
Akeso's Ivonescimab Wins 4th Breakthrough Therapy Nod in China for TNBC
Akeso has secured its fourth Breakthrough Therapy Designation (BTD) in China for Ivonescimab, targeting first-line treatment of triple-negative breast cancer (TNBC). The ongoing Phase III HARMONi-BC1 trial is assessing its safety and efficacy in this hard-to-treat cancer type.
Ivonescimab | 03/11/2025 | By Dineshwori | 134
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy